Innovation Pharmaceuticals Inc.
IPIX · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.04 | -0.28 | 0.35 |
| FCF Yield | -21.41% | -40.72% | -11.50% | -4.37% |
| EV / EBITDA | -3.40 | -2.00 | -8.67 | -15.58 |
| Quality | ||||
| ROIC | -112.55% | -115.00% | -96.10% | -118.30% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.66 | 0.89 | 0.68 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -65.09% | – | – |
| Free Cash Flow Growth | 65.94% | 33.52% | -125.26% | 33.83% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | 0.38 | 0.96 | 0.59 |
| Interest Coverage | -54.58 | -60.18 | -1.86 | -17.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,466.85 | 0.00 | -1,039.96 | 0.00 |